IPO filing research

Apnimed, Inc.

Pharmaceutical Preparations

ipo amended Nasdaq Global Market S-1

Apnimed, Inc. IPO research page with SEC filing history, offering status, deal terms, structured filing extracts, company news, and comparable IPO context. Latest filing: S-1 on 2026-07-10. Current deal snapshot: exchange Nasdaq Global Market.

Filing Timeline

SEC EDGAR

S-1 filed

Initial registration statement

Initial public filing submitted to start the SEC review process.

Follows DRS/A in the pre-IPO sequence.

Common Stock · Exchange Nasdaq Global Market · Ticker APMD · Underwriters BofA Securities, Evercore ISI, Cantor

Apnimed, Inc. outlines significant risks related to the regulatory approval process for its product candidate Oxnimbi, including potential delays or rejections by the FDA due to manufacturing changes, limited indications, or post-marketing requirements. The company emphasizes challenges in clinical trial execution, such as patient enrollment difficulties, regulatory hurdles, and reliance on third-party contractors. Manufacturing uncertainties, limited financial resources, and the inherent risks of drug development are highlighted as critical obstacles to commercialization. The filing underscores the company's focus on Oxnimbi while acknowledging the risks of diverting resources from other potential opportunities.

2026-07-10 · 0001193125-26-300909

DRS/A amended

Amended draft registration statement

Updated draft registration filed before the public launch.

Updates the prior DRS/A filing.

2026-06-01 · 0001193125-26-249229

DRS/A amended

Amended draft registration statement

Updated draft registration filed before the public launch.

Updates the prior DRS/A filing.

2026-04-22 · 0001193125-26-167732

DRS/A amended

Amended draft registration statement

Updated draft registration filed before the public launch.

Updates the prior DRS filing.

2026-02-17 · 0001193125-26-054701

DRS filed

Draft registration statement

Draft registration filed confidentially before the public launch.

First tracked pre-IPO filing for this issuer.

2024-07-01 · 0000950123-24-006348

Comparable Deals

16 comparable deals

Healthcare & BiotechLast 18 months

Only 0 strict matches; expanded to 16 using nearest neighbors.

Showing top 8 by similarity.

-1.3%

Median day-1

50%

Above issue

-1.3%

Median week-1

-20.9%

Downside (p10)

Kardigan, Inc. KARD

2026-06-18 $400M Day 1: +37.5% Wk 1: +41.1%

same SICrecent IPO

Parabilis Medicines, Inc. PBLS

2026-06-10 $670M Day 1: +58.0% Wk 1: +30.2%

same SICrecent IPO

Seaport Therapeutics, Inc. SPTX

2026-05-01 $255M Day 1: +10.2% Wk 1: -13.9%

same SICrecent IPO

Avalyn Pharma Inc. AVLN

2026-04-30 $300M Day 1: +63.8% Wk 1: +53.9%

same SICrecent IPO

First Tracks Biotherapeutics, Inc. TRAX

2026-04-20 - Day 1: -9.3% Wk 1: -11.5%

same SICrecent IPO

Kailera Therapeutics, Inc. KLRA

2026-04-17 $625M Day 1: +62.5% Wk 1: +56.7%

same SICrecent IPO

Generate Biomedicines, Inc. GENB

2026-02-27 $400M Day 1: -20.9% Wk 1: -22.2%

same SICrecent IPO

SL Science Holding Ltd SLBT

2026-06-15 - Day 1: -16.8% Wk 1: +13.0%

same SIC grouprecent IPO

Recent News

No recent news stored for this issuer.